Vorapaxar in the Secondary Prevention of Atherothrombotic Events
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F12%3A00059817" target="_blank" >RIV/00216224:14110/12:00059817 - isvavai.cz</a>
Alternative codes found
RIV/65269705:_____/12:#0001877
Result on the web
<a href="http://dx.doi.org/10.1056/nejmoa1200933" target="_blank" >http://dx.doi.org/10.1056/nejmoa1200933</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/nejmoa1200933" target="_blank" >10.1056/nejmoa1200933</a>
Alternative languages
Result language
angličtina
Original language name
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
Original language description
Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. Methods We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of deathfrom cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. Results At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P&
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Volume of the periodical
366
Issue of the periodical within the volume
15
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
1404-1413
UT code for WoS article
000302608600004
EID of the result in the Scopus database
—